Amylin: the second satiety signal
With every meal your pancreas releases two substances at once: insulin and amylin. The second is far less known but has a role of its own in satiety.
The forgotten partner hormone
Insulin and amylin are made by the same cells and released together. Insulin governs what happens to sugar. Amylin does something else: it slows stomach emptying, curbs glucagon release and sends a satiety signal to the brainstem.
That division of labour is neat. One makes sure the fuel is stored, the other makes sure no more fuel arrives than needed.
Why amylin had a problem
Natural human amylin has an awkward property: it clumps into fibres. In a test tube it forms a gel within a short time. That makes it nearly unworkable as a research substance and was for years the reason little happened with this route.
The solution came from nature. Rat amylin does not clump, because three positions carry a different amino acid. Taking over those three positions produced pramlintide, the first usable variant. Cagrilintide is a later step: also modified against clumping, and with a fatty acid tail that makes it last days instead of minutes.
GLP-1 comes from the gut and responds to what arrives. Amylin comes from the pancreas and responds to what is processed. Both end at satiety, but through different cells and different signals. That is exactly why they are so often combined in research.
The combination
Cagrilintide together with semaglutide is known in the literature as CagriSema. The thinking is simple: engaging two independent satiety routes at once gives a stronger signal than driving one route hard. It is a different strategy from the triple agonists, which try to pack everything into one molecule.
Which of those two approaches wins in the long run is an open question. A combination of two substances lets you change the ratio; a molecule hitting three receptors has that ratio fixed in its structure.
What to check with a blend
If cagrilintide sits in a vial together with a GLP-1 analogue, you are dealing with a mixture, not a substance. A single purity figure says little there. What you want to know is whether the ratio between the two holds and whether both were measured separately. More on that in reading a certificate of analysis.
This site is made by the team behind Apex Bio Research, a Dutch supplier of research peptides with a certificate of analysis per batch.
Visit the shopThis site explains what the scientific literature says about peptides. It is not medical advice and not a set of instructions. The substances discussed here are research compounds: they are not approved for use in humans or animals. If you have a health question, see a doctor.
Read next
GLP-1 and the incretins explained
Why your gut releases hormones the moment you eat, what GLP-1 and GIP actually do, and why a copy lasts longer than the original.
From single to triple agonist
Semaglutide, tirzepatide and retatrutide side by side: which receptors they hit, what each step adds and why glucagon is the newest direction.